Cwm LLC Has $66.27 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Cwm LLC boosted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 52.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,228,590 shares of the biopharmaceutical company’s stock after purchasing an additional 422,041 shares during the quarter. Cwm LLC’s holdings in Bristol Myers Squibb were worth $66,270,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of BMY. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb during the second quarter valued at about $25,000. Harbor Capital Advisors Inc. grew its holdings in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 313 shares during the last quarter. Beacon Financial Strategies CORP acquired a new position in shares of Bristol Myers Squibb during the fourth quarter valued at about $38,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Bristol Myers Squibb during the third quarter valued at about $35,000. Finally, JPL Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb during the third quarter valued at about $36,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of analyst reports. Morgan Stanley reiterated an “underweight” rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Bank of America reduced their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, April 9th. Guggenheim reiterated a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Wall Street Zen cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 11th. Finally, Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price objective for the company. Nine analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and an average price target of $61.71.

Bristol Myers Squibb Stock Down 0.3%

Bristol Myers Squibb stock opened at $57.91 on Thursday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The stock has a market cap of $118.24 billion, a PE ratio of 16.79, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27. The firm’s 50-day simple moving average is $59.87 and its 200 day simple moving average is $53.47. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter last year, the firm posted $1.67 earnings per share. The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.4%. Bristol Myers Squibb’s payout ratio is 73.04%.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.05% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.